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Background: Although the prognosis of localised prostate cancer is good, the negative effects of prostate cancer treatment often
impair patient quality of life. A growing number of men experience these negative effects over a longer time because of the
increased incidence of and prolonged survival in prostate cancer, and the ageing of the population. Only a few studies have
investigated the adverse effects of different prostate cancer treatments using large population-based samples.
Methods: We conducted a nationwide survey (n¼ 1239) to collect detailed information regarding the negative effects (i.e., the
occurrence, perceived level and perceived bother since the beginning of the treatment) of prostate cancer treatments: radical
prostatectomy, external beam radiotherapy, brachytherapy, hormone therapy and surveillance. Furthermore, we measured patient
satisfaction with the outcome of the treatment and their psychological well-being (i.e., psychological symptoms and satisfaction
with life) 5 years after diagnosis. The negative effects between the treatments were compared, and the determinants of
satisfaction and psychological well-being were investigated.
Results: The negative effects of all types of active prostate cancer treatments were common and persistent (33–48% reported
symptoms at 5 years) and showed the known differences between the treatments. Prostatectomy and the radiotherapies caused
urinary leakage; radiotherapy also caused symptoms of urinary irritation; and external radiation also caused bowel dysfunction.
Most symptoms were considered highly bothersome. Most respondents (8193%) reported that their treatment negatively
affected their sex lives; 70–92% reported sexual dysfunction; and 20–58% reported that their sex lives with their spouses had
ended. Urinary symptoms were especially associated with poorer psychological outcomes. The perception of symptom level and
bother had a greater effect on patient satisfaction and well-being than the symptoms per se.
Conclusion: Multiple and persistent negative effects follow active prostate cancer treatment, and these effects predict long-term
patient satisfaction and psychological well-being. The harms and benefits associated with prostate cancer treatments should be
considered when selecting whether and how to actively treat prostate cancer.
Prostate cancer is the most common cancer among men in
developed countries, and 420 000 new cases were diagnosed in
Europe in 2012 (http://globocan.iarc.fr). In Finland, the mean
annual number from 2009–2013 was 4791 cases (www.cancerre-
gistry.fi). The incidence of prostate cancer is increasing worldwide.
This increase is partially because of the widespread testing for
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prostate-specific antigen (PSA; Penson et al, 2008b; van Leeuwen
et al, 2013; Wever et al, 2013; Schro¨der et al, 2014). Most prostate
cancers are detected when they are localised and the prognosis is
good, and the prevalence is increasing also because of the ageing of
the population. Although survival is good, quality of life (QoL)
outcomes are impaired by the negative effects due to various
prostate cancer treatments (Potosky et al, 2004; Miller et al, 2005;
Frank et al, 2007; Penson et al, 2008a, b; Roth et al, 2008; Smith
et al, 2009; Lehto et al, 2010, 2013; Pardo et al, 2010).
Harmful, multiple and persistent adverse effects are common
after all forms of active prostate cancer therapy: radical
prostatectomy, external beam radiation, brachytherapy and
hormone therapy. The most common negative effects include
urinary, sexual and bowel dysfunction, all of which can reduce
patient well-being and QoL (Miller et al, 2005; Northhouse et al,
2007; Penson et al, 2008a, b; Roth et al, 2008; Smith et al, 2009;
Pardo et al, 2010; Lehto et al, 2013; Gavin et al, 2015). The negative
effects vary by treatment method. All active prostate cancer
treatments result in sexual difficulties; prostatectomy and radio-
therapies also in urinary dysfunction; external radiotherapy also in
bowel dysfunction; and hormone therapy causes, for example, hot
flushes and mood disturbances. Consensus does not exist regarding
whether the benefits of active treatment for early prostate cancer,
compared with those of surveillance, outweigh the negative effects
of the treatment (Denberg et al, 2006; Penson et al, 2008b; van den
Bergh et al, 2009; Carter et al, 2015; Klotz et al, 2015).
Various treatment options for prostate cancer follow specific
guidelines such as the European Association of Urology Prostate
Cancer Guidelines (https://uroweb.org/guideline/prostate-cancer)
and the American Urological Association Guidelines (https://
www.auanet.org/education/clinical-practice-guidelines.cfm), which
are based on the risk classification of the disease. However, the best
treatment for long-term survival is still unknown (Wever et al,
2013). Specifically, no randomised controlled trial has compared
prostatectomy with external beam radiotherapy. Patients usually
participate in choosing their own treatments. This choice is
important because different treatments can impair different areas
of well-being and QoL. Differences in professional opinion
concerning the best treatment option might complicate the
situation for the patient at diagnosis (Denberg et al, 2006; Roth
et al, 2008; Wever et al, 2013; Sooriakumaran et al, 2014). Both the
prognosis and effect of the treatment on QoL should be considered
when choosing a treatment for prostate cancer (Damber and Aus,
2008; Roth et al, 2008; Wever et al, 2013). Many men with localised
prostate cancer do not benefit from definitive treatment (European
Association of Urology Prostate Cancer Guidelines), and not all
early local or locoregional prostate cancers require active treatment
(Bul et al, 2013; Wever et al, 2013; Carter et al, 2015). In addition,
the harms and benefits of population PSA screening are currently
widely discussed (Auvinen et al, 2016). Screening with PSA detects
some early prostate cancers that would never cause significant
clinical problems during a man’s lifetime. More information is
needed to minimise the negative effects of prostate cancer and its
treatments.
Using a population-based sample of men with prostate cancer
diagnosis, we collected comprehensive information concerning the
patient-reported negative effects (i.e., occurrence, perceived level
and the perceived bother of the symptoms at any time, ‘ever’ and
‘current’) of different prostate cancer treatments 5 years after
diagnosis. We also measured patient satisfaction with the outcome
of the treatment and their psychological well-being (i.e., psycho-
logical symptoms and satisfaction with life) 5 years after diagnosis.
The negative effects of the different treatments were compared, and
the association among these negative effects, patient satisfaction
and well-being was investigated.
PATIENTS AND METHODS
Sample and procedure. The Finnish Cancer Registry (www.can-
cerregistry.fi) collected a nationwide sample of every second
incidence case diagnosed in Finland in 2004 on our behalf (Lehto
et al, 2010; Lehto et al, 2015; Figure 1). We linked these data with
the Finnish Population Register Centre and excluded patients who
died before survey. After excluding patients without a recommen-
dation from the treating hospital to participate in this study (11%),
and those whose address was not available, we mailed a
questionnaire to 1723 men between January and May 2009.
A telephone line was provided to the patients for questions. A
further questionnaire was sent to non-respondents 1 month later.
We accepted 1239 returned questionnaires (72%) for the study
(Figure 1). These questionnaires represented 62.5% of the patients
(n¼ 1984) who were alive at the time of the survey (70% of those
who were o65 years old, 67% of those who were 65–74 years old,
60% of those who were 75–84 years old, and 34.5% who wereX85
years old). The response rate and the age distribution of the
2 168 newly diagnosed prostate cancer cases
dignosed in Finland in 2004
50% (every second) sample from the Finnish Cancer Registry
31 no postal address available
- One further questionnaire 1 month later
Eight further deaths
1 242 returned questionnaires
1 239 accepted questionnaires
3 excluded due to earlier prostate cancer diagnosis
The survey qusetionnaire mailed to 1 723 men between
January and May 2009
181 had died before the survey (January 2009) → n= 1987
233 no recommendation obtained from hospital in charge for
treatment 
Figure 1. The study sample.
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patients was similar across the five university hospital districts
(geographic regions) in Finland (Lehto et al, 2010).
The questionnaire. The questionnaire was designed for the
purposes of this study and constructed in collaboration with
members of a prostate cancer patient organisation (Eturauhassyo¨-
pa¨potilaiden tuki ry ERSY). These patients also participated in pilot
studies to develop the questionnaire. The results of the first section
of the questionnaire were previously reported (Lehto et al, 2015).
The second section targeted the negative effects due to the
treatment. We measured the occurrence, perceived level and the
perceived bother of a given adverse effect at any time (ever) since
the treatment with regard to each type of treatment the patient
received, including radical prostatectomy, radiotherapies (i.e.,
external beam radiotherapy or brachytherapy), hormone therapy
(other than neoadjuvant) and surveillance. (If any doubt or
inconsistency appeared in the survey, then an expert medical
researcher checked the treatment(s) implemented using the
information the patient provided in the questionnaire or the
information in the cancer registry data.). They were also asked
whether the cancer had recurred.
The degree of the negative effects was evaluated with scales
ranging from 0 (not at all) to 3 (a lot/strong/all the time) or with
dichotomous no/yes answers. The patients were also asked whether
they had had sex life with their spouse 6 months before the
diagnosis (no/yes) and at any time after treatment (no/yes). Patient
satisfaction was assessed using a scale ranging from 1 (completely
adequate/satisfied) to 4 (completely inadequate/dissatisfied). Some
open-ended questions including one regarding the negative
effect(s) that the patient still suffered at the time of the survey
were also asked.
Patient satisfaction with the overall outcome of the treatment
and their psychological well-being were measured at the time of the
survey. The patients indicated how satisfied they were with the
outcome of their treatment using a scale ranging from 1
(completely satisfied) to 4 (completely dissatisfied). Psychological
well-being was measured using two validated measures (Lehto et al,
2015): the psychological symptom items of the cancer-specific
Rotterdam Symptom Checklist (deHaes et al, 1990), including
irritability, depressed mood, nervousness, desperate feelings about
the future, tension, anxiety, difficulty concentrating and worrying
with scales ranging from 0 (not at all) to 3 (much), and the
Satisfaction With Life Scale including statements: In most ways, my
life is close to my ideal; The conditions of my life are excellent; I
am satisfied with my life; So far I have the important things I want
in life; If I could live my life over, I would change almost nothing
(Diener et al, 1985).
We analysed the data using descriptive statistics and investi-
gated the associations between the negative effects of the treatment
and the outcome measures (i.e., satisfaction with outcome of the
treatment, psychological symptoms and satisfaction with life) using
a linear regression analysis (B¼ regression coefficient). All
statistical analyses were performed using SPSS version 22 and
Stata version 11.
Permissions and ethical aspects. The Ministry of Social Affairs
and Health in Finland provided permission to obtain the Finnish
Cancer Registry patient data. Experts in health psychology revised
the questionnaire, and it was mailed to the patients from the
National Public Health Institute (currently THL). The Ethics
Committee of Helsinki University Hospital approved the research
protocol.
RESULTS
The mean age of the respondents was 72 years old (range, 49–98
years), and thus the mean age at diagnosis has been 67 years old
(Table 1; Lehto et al, 2010, 2015). Approximately 80% were
married or cohabiting, and 88% were retired. Nearly half (47%)
reported receiving no or a very brief vocational education.
Approximately 75% reported that they had another chronic
condition (Table 1).
The most common treatments were radical prostatectomy
(26%) and external beam radiation (24%) implemented as a
single therapy (Table 1). Hormone (androgen deprivation)
therapy was often used as an adjuvant treatment. However,
23% of the patients had undergone multiple treatments; thus, the
total use of the different treatment modalities (alone or in
combination) was higher. A total of 42% of the respondents
received external beam radiotherapy, 33% received hormonal
therapy, 32% received radical prostatectomy, 7% received
surveillance and 6.5% received brachytherapy (Lehto et al,
2015). Hormonal therapy was often (65%) still going on at the
time of the survey. Age was positively associated with hormonal
therapy and surveillance but negatively associated with prosta-
tectomy and brachytherapy. Having no other chronic condition
was associated with prostatectomy. The Gleason score was
positively associated with external radiotherapy and hormonal
Table 1. Demographic characteristics of the survey samplea
and treatment for the prostate cancer (N¼ 1239)
% (n)
Age
p64 20 (248)
65–74 41 (503)
75–84 34 (423)
85 and over 5 (65)
Marital status
Married or cohabiting 80 (988)
Divorced 7 (82)
Widow 8 (97)
Never married 4 (45)
Vocational educationb
No vocational education 25 (305)
Vocational courses or school 38 (465)
Some college or college graduate 21 (256)
University degree 14 (169)
Other chronic condition (own report)
Any 74 (900)
Coronary heart disease 26 (311)
Musculoskeletal disease 18 (213)
Diabetes 15 (181)
Other cancer 7 (86)
Other 22 (267)
Gleason classification (xþ x)c
4 or less 10 (131)
5–6 40 (504)
7 26 (326)
8–10 13 (133)
Treatment for prostate cancer
Radical prostatectomy alone 26 (319)
External beam radiotherapy alone 24 (292)
Hormonal therapy aloned 16 (202)
External beam radiotherapyþhormonal therapy 13 (163)
Surveillance alonee 6 (69)
Brachytherapy alone 5 (67)
Prostatectomy þ external beam radiotherapy 4 (50)
Other combination 5 (73)
Note: some variables do not add up to 100% due to missing data.
aFinnish population is ethnically homogeneous in the age groups in question.
bThe education level varied between the geographical areas in favour to the capital Helsinki
area.
cFrom the Cancer Registry data, available for 88.3% of the respondents.
dIncluding orchiectomy.
eEither active surveillance or watchful waiting.
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therapy but negatively associated with brachytherapy and
surveillance. Six per cent of the patients reported that their
prostate cancer had recurred; however, a higher proportion
reported additional treatments, which were obviously due to a
relapse.
Negative effects of the treatments. The negative effects by
treatment are shown in Table 2. Patients treated with prostatect-
omy and radiotherapies commonly reported urinary and sexual
difficulties, and those with external radiotherapy reported also
bowel dysfunction. Depending on the treatment, 33–48% reported
at least one current negative effect after 5 years, and this was more
common after prostatectomy (B¼ 0.17, Po0.001) and external
radiotherapy (0.13, Po0.001) but less common after brachyther-
apy (B¼  0.01, Po0.01).
Urinary dysfunction. More than 70% of the patients reported
urinary leakage after prostatectomy, andB45% of those who were
treated with external radiation or brachytherapy (Table 2). This
symptom was more common after prostatectomy and external
radiation (Po0.001). This difference remained after adjusting for
age. The perceived level of the leakage was also highest after
prostatectomy (Figure 2A). Of those who received prostatectomy,
40% reported that the leakage had ceased within 3 months
(Table 2), whereas 42% of patients receiving external radiation
suffered from leakage for more than a year, and 50% of those
patients reported that this symptom began as a late effect after the
radiation therapy was over. Approximately 10% of the patients had
urinary trouble (a qualitative report) at the time of the survey after
prostatectomy, followed by 8% after external radiation, and 6%
after brachytherapy. Approximately half of all patients reported
that they had experienced unpleasant smell. This effect was more
common after prostatectomy (age and Gleason score adjusted
B¼ 0.29, Po0.001) and less common after brachytherapy
(B¼  0.09, P¼ 0.086).
Additional urinary symptoms, including burning during urina-
tion, increased frequency or blood in the urine, and retention or
straining, were reported after radiation therapy, that is, external
radiation and brachytherapy (Table 2). Brachytherapy was more
closely associated with burning (B¼ 0.36, Po0.001), increased
frequency or blood in the urine (B¼ 0.23, Po0.1) and urinary
retention (B¼ 0.31, Po0.01) than external radiation. Increased
frequency/blood in the urine usually started during the radio-
therapy, and it lasted longer than 1 year for 37% (external
radiation) and 25% (brachytherapy) of the patients. Urinary
retention lasted longer than a year for 30 and 44% of patients.
The urinary symptoms bothered 74 80% of the patients who
reported them, and 7–10% reported these symptoms as a major
bother (Table 2). The degree of the overall bother was predicted by
most of the symptoms in prostatectomy and external radiation
(Table 3). The most troublesome (Po0.001) was the perceived
level of the leakage; after prostatectomy also the level of the smell
and after external beam radiotherapy also increased frequency/
blood in the urine and retention were closely associated (Po0.001)
with the perceived overall bother. Age decreased the perceived
bother of the urinary symptoms after prostatectomy (Po0.01).
Bowel dysfunction. Approximately half of the patients suffered
from bowel dysfunction during or after external beam radio-
therapy, whereas only 15% did so after brachytherapy (Table 2).
The most common symptoms were diarrhoea and bleeding from
the anus/bowel. Diarrhoea lasted less than 3 months in
approximately half of the patients after external radiation; however,
it lasted longer than a year in 32%, and it started as a late effect in
25% of the patients. The bleeding was over in 3 months in 26% of
the patients, whereas it lasted for more than a year in 59%.
Approximately 15% of the patients reported bowel dysfunction at 5
years after external beam radiotherapy, whereas only 4% reported
this symptom after brachytherapy. Bowel dysfunction symptoms
were considered harmful by 90% of the patients. Duration of
diarrhoea was associated with the perceived bother of the bowel
dysfunction (B¼ 0.24, P¼ 0.021).
Negative effects on sex life. All active treatments considerably
affected patients’ sex lives; specifically, 81 93% of respondents
reported an effect (Table 2 and Figure 2B). Prostatectomy was
reported as having a stronger effect on patients’ sex lives (’ever’
during the 5 years after diagnosis) than the other treatments, even
after adjusting for age and the Gleason score (B¼ 0.23, Po0.001).
External beam radiotherapy (B¼  0.16, Po0.001) and hormonal
therapy (B¼  0.29, Po0.001) had weaker effects. Of the patients
who reported a permanent effect at five years, 67% indicated sexual
difficulties after prostatectomy, and almost the same proportion
after brachytherapy (Table 2). Permanent sexual difficulties were
reported more often after prostatectomy (in 32% of all the patients)
than after external radiation (11%) and brachytherapy (20%).
Between 70 and 92% of the patients reported sexual dysfunction
(impotence, loss of libido/sexual desire, or the loss of both potency
and desire) depending on the treatment received (Table 2).
More dysfunction was reported after prostatectomy (B¼ 0.18,
Po0.001, adjusted for age), hormonal therapy (B¼ 0.11,
Po0.001), and external radiotherapy (B¼ 0.07, P¼ 0.006) than
after the other treatments. Between 22 and 57% of the respondents
reported impotence, most often after prostatectomy, whereas loss
of sexual desire alone was rare (4–10%; Figure 2C). 18–25%
reported the loss of both desire and potency after prostatectomy or
radiotherapy, whereas 45% reported the loss of both after
hormonal therapy.
Between 62 and 82% of the respondents reported having sex
life with their spouse before treatment for prostate cancer
(Table 2 and Figure 2D). Younger respondents (B¼  0.02,
Po0.001) and those without a comorbid chronic condition
(B¼ 0.10, P¼ 0.002) reported having sex more often. A prior sex
life had been most common when the chosen treatment was
prostatectomy (B¼ 0.13, Po0.001, when adjusted for age, the
Gleason score and the presence of another chronic condition) but
less common when it was surveillance (B¼  0.45, Po0.001).
The patients’ sex lives decreased considerably after all treatments,
and it ended in 38%, 30%, 20% and 58% of the patients receiving
prostatectomy, external radiation, brachytherapy and hormone
therapy, respectively. A post-treatment sex life was more
common after radiation therapy (52 and 69% for external
radiation and brachytherapy, respectively). 28% of the patients
receiving hormone therapy reported having sex life with their
spouse after treatment.
Across the different treatments, slightly different sexual effects
predicted the overall effect of the treatment on sex life (Table 3).
The most harmful effects across all treatments (Po0.001) were the
loss of both sexual desire and potency and the loss of sexual desire.
The loss of potency showed a weaker association. A pre-treatment
sex life with the spouse naturally predicted a stronger effect on sex
life and the effect was weaker when post-treatment sex life was
present. Age decreased the effect on sex life after prostatectomy
(Po0.1) and hormonal therapy (Po0.01).
Side effects of hormonal therapy. The most common negative
effect of hormonal therapy was hot flushes (73%) followed by sore
breasts (52%), mood disturbances (46%) and oedema of the feet
(34%; Figure 2E).
Patient satisfaction with the outcome of the treatment,
psychological well-being, and the negative effects. Dissatisfac-
tion with the treatment outcome at the time of the survey (i.e.,
proportion of patients reporting any amount of dissatisfaction) was
highest after prostatectomy (42%). 34% of the patients were
dissatisfied with the outcome of hormone therapy, 24% were
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dissatisfied with the outcome of external beam radiation, 22%
were dissatisfied with the outcome of brachytherapy and 15% were
dissatisfied with the outcome of surveillance. The scale means
were 1.55 (s.d.¼ 0.76), 1.48 (s.d.¼ 0.79), 1.35 (s.d.¼ 0.72), 1.34
(s.d.¼ 0.77), respectively, for the active therapies (satisfaction with
surveillance was measured as no/yes).
Three-quarters of the respondents reported at least one
psychological symptom (the Rotterdam Symptom Checklist) at
Table 2. Negative effects in different treatments
Prostatectomy
(n¼402)
External beam
radiation (n¼523)
Brachy therapy
(n¼80)
Hormone therapy
(n¼412)
Urinary tract symptoms
Urinary leakage
Reported: % 71 44 47 –
Perceived level: mean (s.d.) 1.07 (0.89) 0.64 (0.83) 0.73 (0.91) –
Duration: %
o3 Months 40 18 20 –
3–6 Months 13 8 9 –
6–12 Months 6 12 29 –
41 Year 30 42 34 –
No information 12 21 9 –
Smell effect of urinary leakage: % 59 58 41 –
Perceived level of smell effect: mean (s.d.) 0.78 (0.74) 0.75 (0.76) 0.51 (0.70) –
Burning during urination
Reported: % – 29 51 –
Perceived level: mean (s.d.) – 0.36 (0.61) 0.72 (0.84) –
Increased frequency or blood in urine
Reported: % – 46 61 –
Perceived level: mean (s.d.) – 0.73 (0.90) 0.89 (0.85) –
Urinary retention or straining
Reported: % – 30 44 –
Perceived level: mean (s.d.) – 0.45 (0.77) 0.73 (0.96) –
Bother of the urinary symptoms
Reported, all above % 80 74 74 –
Perceived level of bother: %
Not at all 20 21 25 –
A little 47 34 43 –
Somewhat 24 25 18 –
A lot 7 7 10 –
No information 3 12 3 –
Level of bother, mean (s.d.) 1.10 (0.82) 1.16 (0.93) 1.08 (0.94) –
Bowel dysfunction
Bowel symptoms totala – 53 15b –
Diarrhoea
Reported: % – 77 36 –
Duration: %
o3 Months – 47 25 –
3–12 Months – 17 25 –
41 Year – 32 50 –
Bleeding from anus
Reported: % – 41 64 –
Duration: %
o3 Months – 26 33 –
3–12 Months – 15 17 –
41 Year – 59 50 –
Bother of bowel symptoms
Reported : % – 88 91 –
Perceived level of bother. %
Not at all – 12 9 –
A little – 41 55 –
Somewhat – 36 18 –
A lot – 11 18 –
Level of bother: mean (s.d.) 1.45 (0.86) 1.45 (0.93) –
Impact on sex life
Impact in sex life
Reported: % 93 82 86 81
Perceived level: mean (s.d.) 2.35 (0.91) 1.89 (1.13) 1.78 (1.08) 2.16 (1.18)
Sexual dysfunction
Reported total: % 92 79 70 84
Impotence 57 34 33 22
Loss of sexual desire 4 8 10 7
Loss of desire and potency 18 25 18 45
Sex life with spouse
During 6 months before the treatment: %
No 10 23 16 28
Yes 82 70 81 62
No spouse 8 7 3 10
After the treatment: % 55 52 69 28
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the time of the survey (total scale mean¼ 4.39, SD¼ 4.6; Lehto
et al, 2015). The most common symptom was worrying (57%),
followed by irritability (46%), nervousness (40%) and problems
concentrating (39%). Regarding the satisfaction with life state-
ments (the Satisfaction With Life Scale), the median response
was ‘mostly agree’. Brachytherapy was associated with a lower
total level of psychological symptoms, whereas surveillance was
associated with greater satisfaction with life (Lehto et al, 2015).
Age was negatively associated with the total level of the
psychological symptoms (B¼  0.05, Po0.05 when adjusted
Table 2. (Continued)
Prostatectomy
(n¼402)
External beam
radiation (n¼523)
Brachy therapy
(n¼80)
Hormone therapy
(n¼412)
A permanent negative effect (at 5 years)
A permanent negative effect reported: %
No 43 48 53 –
No information 9 15 15 –
Yes 48 37 33 –
The effects classified from qualitative reports %:
Impotence or sexual difficulties 67 30 62
Need for medication (tablet, injection) to get erection 9 2 8
Urinary leakage or increased frequency 20 21 19
Bowel symptoms 1 39 12
Pain in lower abdomen/back/the scar 5 5 4
Note: all symptoms were not asked from all treatments, because some symptoms are mostly treatment-specific.
aData in brachytherapy insufficient (over 50% missing values).
bN¼ 11.
53,3
55,9
7,8
28,7
20,4
28,1
12,6
3,5
24,0
43,1
*Age associated with increased urinary leakage (F = 2.96, P = 0.032).
Not at all A little Somewhat Much
Mood disturbances *
Hot flushes/ swetting *
Sore breasts *
Oedema of the feet
53,9
26,5
16,2
3,4
3,5
10,3
20,1
19,9
28,1
24,5
20,2
48,3
27
7
25
External
radiation
72,3
4,4
23,3
12,3
50,9
36,9
16,7
54,2
29,2
Loss of desire only
Potency deficiency after the different treatments, %
Loss of potency only Loss of both
C
Prostatectomy
(92%)
Brachytherapy
(70%)
External radiation
(79%)
Not at all A little All the timeSometime/somewhat
Urinary leakage after different treatments (age-adjusted), %A
Perceived impact on sex-life (age-adjusted),%
* Age decreased the impact.
* Associated with younger age.
29,6
61,5
8,9
Sex life with the spouse before and after the treatments, %
B D
E
No impact A little Somewhat Strong
Prostatectomy *(n = 402)
6,8
9,6
25,2
25,2
40,8
14,5
27,6
23,7
34,2
66,1
18,6
7,4
13,3
18,2
15,9
58,4
60,8
90
80
70
60
50
40
30
20
10
0
Prostatectomy Brachytherapy
Hormone therapy
(84%)
Hormonal
therapy
No spouse
Sex-life with spouse during 6
months before the treatment
Sex-life with spouse after the 
 treatement
External radiation *(n = 523)
Hormonal therapy *(n = 412)
Brachytherapy (n = 80)
Prostatectomy *
4,0
18,7
External radiation
Brachytherapy
Figure 2. Negative effects in different treatments (Reproduced by kind permission Lehto et al, 2013). (A) Urinary leakage after different
treatments (age-adjusted), %. (B) Perceived impact on sex life (age-adjusted), %. (C) Potency deficiency after different treatments, %. (D) Sex life
with the spouse before and after the treatment, %. (E) Adverse effects of hormonal treatment, %.
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for treatment modality and recurrence). Reported recurrence
was associated with more psychological symptoms (B¼ 1.14,
Po0.05).
Across the different treatments, different negative effects were
associated with the outcomes (i.e., dissatisfaction with the
treatment outcome and the well-being indicators (Table 4). The
perceived level and the perceived bother of the symptoms (e.g.,
levels of bother of the urinary leakage and smell effect of the
urinary leakage) were more strongly associated with the outcomes
than the occurrence of the symptoms (measured as no/yes). Sexual
dysfunction effects were more associated with the well-being
outcomes among patients receiving prostatectomy than those
receiving the other treatments. Sexual effects were of little
consequence among the patients receiving radiation therapies,
and their urinary symptoms explained most of the variation in the
psychological well-being.
DISCUSSION
This nationwide survey collected detailed information regarding
the negative effects of prostate cancer treatment by investigating
patient perceptions of these effects and their bother at any time
since the treatment during 5 years after diagnosis. We also
measured patients’ levels of satisfaction and psychological well-
being five years after diagnosis. A 50%-patient sample from a
national cancer registry enabled us to study all men in Finland who
were diagnosed with prostate cancer over 1 year. The response rate
was high (72%) for a postal survey addressing relatively elderly
people. Of the patients in the cancer registry, 62.5% replied to our
survey; only those over 84 years old were under-represented. The
sample was representative of prostate cancer survivors 5 years after
diagnosis. Along with the recent work from Ireland (Gavin et al,
2015), the current study is one of the first to describe the negative
consequences of the various prostate cancer treatments in a
population sample of patients of all ages.
As previously reported, the negative effects of all types of active
prostate cancer treatments were common, often multiple, and
persisted over the long term (Miller et al, 2005; Smith et al, 2009;
Pardo et al, 2010; Resnick et al, 2013; Gavin et al, 2015). The
known differences by treatment method were as follows:
prostatectomy and the radiotherapies cause urinary symptoms;
external beam radiotherapy also causes bowel dysfunction; and all
active treatments were followed by sexual difficulties. Some of the
treatments typically induce immediate transitory side effects
(prostatectomy) and some treatment-specific late effects (radio-
therapies), and all treatments result in long-term effects. We found
that most of the adverse effects were considered highly bother-
some. Approximately 75% of the patients stated that their urinary
symptoms bothered them, and 90% stated that their bowel
dysfunction was bothersome. All treatments had the potential to
seriously harm the patients’ sex lives.
Because we recorded all negative effects since the beginning of
the treatment, our study found high levels of negative effects when
compared with previous research (Lehto et al, 2013). We do not
have information regarding when most of these negative effects
occurred during the 5 years or whether they had passed; however,
we have qualitative data concerning the negative effects present at
the time of the survey. Several studies have measured side effects at
a specific time point (Potosky et al, 2004; Miller et al, 2005; Penson
et al, 2008a; Smith et al, 2009; Pardo et al, 2010; Gavin et al, 2015)
and reported that there were more negative effects after
prostatectomy than after other treatments at 3 years (Smith et al,
2009; Pardo et al, 2010) or at 5 years (Potosky et al, 2004; Penson
et al, 2008a) post-diagnosis/treatment. This finding is in agreement
with our results. However, one study (Miller et al, 2005) reported
few differences between prostatectomy and external beam radio-
therapy after six years. More recently, no significant differences in
urinary, bowel or sexual function were found between prostatect-
omy and radiotherapy when evaluated at 15 years (Resnick et al,
2013).
The high level of urinary leakage experienced by patients
receiving prostatectomy was often decreased quickly, and perma-
nent urinary troubles were only slightly more common after
prostatectomy than after external beam radiotherapy or bra-
chytherapy. Age was negatively associated with the perceived
Table 3. Associations between the urinary and sexual adverse effects and overall perceived bother of them
Prostatectomy External radiation Brachytherapy Hormonal therapy
B B B B
Level of total bother of the urinary symptoms
Predictors
Age  0.02** 0.01 0.02
Gleason 0.04 0.09w 0.12
Level of urinary leakage 0.39*** 0.40*** 0.13
Duration of urinary leakage 0.10** 0.18** 0.13
Smell effect of urinary leakage 0.44*** 0.17 0.10
Burning during urinating 0.01 0.33
Frequency or blood in urine 0.24*** 0.04
Retention or straining 0.24** 0.38w
Coefficient of determination R2 for the model 0.49 0.46 0.40
Level of impact of treatment on sex life
Predictors
Age  0.01w 0.01 0.03 0.02**
Gleason 0.04 0.06 0.05 0.03
Impotence 0.64** 0.59*** 0.38 0.83**
Loss of sexual desire 1.11*** 1.19*** 1.16*** 1.44***
Loss of both desire and potency 1.19*** 1.41*** 1.50*** 1.79***
Sex life with spouse during 6 months before treatment 0.18 0.65*** 0.38 0.38**
Sex life with spouse after treatment  0.20* 0.22* 0.05 0.36*
Coefficient of determination R2 for the model 0.31 0.36 0.40 0.38
Note: B¼ regression coefficient: association between the negative effects/symptoms and overall bother of them, by linear regression analysis, adjusted for age and Gleason, all variables in the
model. ***P-value o0.001, **P-value o0.01, *P-value o 0.05, w P-value o0.1.
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bother of the urinary symptoms, which suggests that these
symptoms are better tolerated as patients grow older age. However,
prostatectomy most strongly affected patients’ sex lives. Operation
typically resulted in sexual dysfunction, especially impotence
(75%), whereas impotence was less frequently associated with the
other treatments (51–67%). The patients reported far more often
permanent sexual difficulties after prostatectomy (32%) than after
external radiation and brachytherapy (11% and 20%, respectively).
This number was even higher when troubles solved with
medication were included. This finding corroborates those of
Table 4. Negative effects of treatments associated with dissatisfaction with outcome of the treatment and psychological well-
being
Dissatisfaction with the
outcome
Psychological symptoms Satisfaction with life
B P B P B P
A. Negative effects predicting psychological outcomes in prostatectomy
Predictors
Age  0.01 0.077 0.12 0.021
Gleason 0.65 0.032
University education 0.27 0.026
Have spouse 3.16 0.002
Musculoskeletal disease 2.07 0.032  3.72 0.001
Bother of urinary leakage 0.22 o0.001  1.28 0.017
Smell effect of urinary leakage 1.14 0.010  1.11 0.063
Impact on sex life 0.15 0.008  1.29 0.003
Sex life with spouse during 6 months before treatment 0.20 0.062
Sex life with spouse after the treatment 1.39 0.029
A permanent negative effect 0.25 0.011 1.38 0.025
Coefficient of determination R2 for the model 0.22 0.13 0.22
B. Negative effects predicting psychological outcomes in external beam radiotherapy
Predictors
Age 0.12 0.074
Gleason 0.65 0.070
University education 0.41 0.067
Have children 4.04 0.003
Musculoskeletal disease  1.97 0.092
Urinary leakage 0.91 0.092
Smell effect of urinary leakage 0.36 0.004  1.33 0.026
Burning during urinating 0.22 0.092 1.43 0.024
Urinary frequency or blood in urine  1.32 0.004
Late effect urinary frequency or blood in urine 2.36 0.014
Impotence 0.33 0.080
Bother of bowel dysfunction 0.23 0.022 1.11 0.044
A permanent negative effect 0.52 0.003
Satisfaction with sex life 1.03 0.005
Coefficient of determination R2 for the model 0.34 0.27 0.26
C. Negative effects predicting psychological outcomes in brachytherapy
Predictors
Age 0.20 0.052
University education 4.94 0.021
Smell effect of urinary leakage 3.16 0.001
Duration of urinary leakage  1.33 0.056
Duration of urinary frequency or blood in urine 0.29 0.030
Bother of urinary symptoms  1.52 0.078
Coefficient of determination R2 for the model 0.26 0.33 0.34
D. Negative effects predicting psychological outcomes in hormonal therapya
Predictors
Age 0.06 0.081
University education  0.46 0.016 1.39 0.051
Have spouse 1.08 0.068
Musculoskeletal disease  2.77 0.006
Diabetes 1.30 0.049
Sex life with spouse during 6 months before treatment 0.21 0.032  1.49 0.074
Loss of sexual desire 2.08 0.034
Mood disturbances 0.17 0.027 2.88 o0.001
Sore breasts 0.19 0.007
Oedema of feet 0.19 0.012
Other symptom of hormonal treatment 0.24 0.074
Satisfaction with sex life 1.08 o0.001
Coefficient of determination R2 for the model 0.27 0.32 0.14
Note: B¼ regression coefficient: association between negative effects and the well-being outcome (dissatisfaction with the outcome of treatment, psychological symptoms, satisfaction with
life), by linear regression analysis. All variables adjusted for age and Gleason (in brachytherapy, Gleasonp7). Only the statistically significant are given.
aIn 65% of the patients with hormonal therapy the treatment was going on.
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previous studies (Potosky et al, 2004; Smith et al, 2009), indicating
that prostatectomy often induces sexual dysfunction. The effect of
prostatectomy on patients’ sex lives was most likely stronger
because these patients were younger, were more likely to have a sex
life before treatment, and less likely to suffer from another chronic
condition. Furthermore, prostatectomy typically led to impotence
without the loss of sexual desire, which was strongly associated
with perceived bother.
Among patients receiving external beam radiotherapy, urinary
trouble and bowel dysfunction often started as a late effect after the
treatment. Half of the patients reported bowel dysfunctions
(diarrhoea or anal bleeding), and 25% reported these effects as
late, and often lasting for more than a year. In addition, 15%
reported bowel dysfunction after 5 years. The frequency of bowel
dysfunction reported here matches previous reports, that is, 15–
23% after 3 years (Smith et al, 2009; Pardo et al, 2010) and 13%
after 6 years (Miller et al, 2005). The absence of a sex life with one’s
spouse occurred less frequently after radiotherapy than after the
other treatments. Approximately half of the patients who under-
went external beam radiotherapy reported having a sex life with
their spouse after the treatment; this decrease was small because
only 70% reported a pre-treatment sex life.
Brachytherapy seemed less harmful than the other treatments; it
rarely resulted in bowel dysfunction, and its effect on patients’ sex
lives was smaller than those of other treatments. However, urinary
irritation symptoms (burning, frequency and retention) remained
common. These patients differed from others with regard to many
preceding factors: they were younger, their cancers had better
prognoses (i.e., smaller Gleason score; high-risk prostate cancer is
not treated with brachytherapy), and they commonly reported pre-
treatment sex lives. A comparison with the other treatments is
complicated because brachytherapy was available only in certain
hospital districts and it was widely used in one district. We
previously found that psychological well-being after brachytherapy
is better than that after other treatments (Lehto et al, 2015). Several
studies have reported that brachytherapy causes fewer long-term
side effects, especially sexual dysfunction and urinary incontinence
(Frank et al, 2007; Aaltomaa et al, 2009; Pardo et al, 2010).
Surprisingly, patients receiving androgen deprivation therapy
reported that their sex life was not more frequently affected than
those receiving the other treatments; however, these patients were
more likely to report a ‘strong’ effect. Age reduced the effect of
hormonal therapy on sex life, and because only 62% of these
patients reported having a sex life before treatment, they likely
already had given up their sex life before their diagnosis, for
example, due to ageing, illness or limitations in functional capacity.
Thus, they had less sex lives to be affected. The decrease in having
sex life with their spouse was nearly 60% of these patients;
however, as many as 28% reported having a sex life with their
spouse since the beginning of treatment.
We found that the negative effects of active prostate cancer
treatment are associated with later satisfaction and psychological
well-being. Urinary symptoms were more strongly associated with
well-being outcomes than sexual difficulties. This result should not
be generalised across all prostate cancer patients; individual
differences in this matter are most likely strong. The association
between sexual dysfunction and the treatment outcomes was
somewhat stronger among patients receiving prostatectomy than
those receiving other treatments. Some positive association was
found between the Gleason score and better well-being. Could it be
that patients with more severe diseases tolerate more negative
effects of the treatment? On the whole, the perceived level and
bother of the symptoms had a stronger effect on psychological
outcomes than the occurrence of the symptoms per se.
We retrospectively measured the negative effects 5 years after
the diagnosis of prostate cancer, and there may have been memory
bias in the patients’ recall of these effects. This might have biased
some of our findings. More severe and longer lasting effects might
be better recalled than short-term consequences. However, the
disturbing adverse effects due to cancer treatment are likely to be
remembered, even years later. We assessed the effects associated
with each treatment; however, nearly 25% of the patients received
multiple treatments. Thus, these patients might have difficulty
separating the effects of individual treatments from each other.
Furthermore, we did not always ask when the symptoms occurred
or how long they lasted (and when we did, the patients’ answers
tended to be incomplete). The current symptoms were recorded
only as the presence of a negative effect at the time of the survey via
quantitative reports that we classified later. The negative effects
and well-being outcomes were measured simultaneously; thus,
their associations do not allow for direct conclusions regarding
causality. In addition, it would have been preferable to have
information about the same symptoms in the population. These
data would have helped assess the effects of prostate cancer
treatment compared with the symptoms of same-aged men.
Our results describe the negative effects of the treatments
implemented in 2004 and 2005. The treatments have developed
since then; however, we believe that prostate cancer patients and
survivors still face many of these negative effects. We believe that
our results also indicate the present situation, especially by
illustrating the perceived harmfulness and bother of the symptoms.
However, a new survey should be conducted to obtain up-to-date
information concerning the negative effects of prostate cancer in
the population and to assess the effects of the developing
treatments.
The abundance of the symptoms and their bothersome nature
draws attention to the harms and benefits of the active treatment of
prostate cancer. An on-going debate exists regarding how and
whether to actively treat patients with early-stage prostate cancer
(Denberg et al, 2006; Bul et al, 2013; Wever et al, 2013; Carter et al,
2015; Klotz et al, 2015). A related discussion concerns the
appropriateness of population PSA screening for prostate cancer
(van Leeuwen et al, 2013; Schro¨der et al, 2014; Auvinen et al, 2016).
Prostate cancer and its associated treatments affect the lives of
an increasing proportion of the elderly male population and their
partners (Lehto et al, 2017). A growing number of men experience
the negative effects of these treatments and for a longer time. Thus,
the well-being of prostate cancer patients and prostate cancer
survivors is also important from a public health perspective. The
negative effects of the treatments described herein and their effects
on well-being should be carefully considered when selecting a
treatment for prostate cancer. In addition, methods should be
developed to alleviate the negative effects associated with
treatments and promote the QoL of men with prostate cancer
diagnosis.
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